

Terri S Armstrong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3551381/terri-s-armstrong-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190
papers

8,288
citations

48
h-index

88
g-index

205
ext. papers

10,175
ext. citations

4.2
avg, IF

5.89
L-index

#	Paper	IF	Citations
190	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.. <i>Acta Neuropathologica</i> , 2022 , 143, 403	14.3	1
189	Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.. <i>CNS Oncology</i> , 2022 , CNS83	4	0
188	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 269-282	3.1	0
187	Opportunities and Challenges for the development of 'Core Outcome Sets' in Neuro-Oncology.. <i>Neuro-Oncology</i> , 2022 ,	1	1
186	A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 21, 100449	5.1	3
185	Accrual and access to neuro-oncology trials in the United States.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vda0048	0.48	0
184	Differences in Circulating Extracellular Vesicle and Soluble Cytokines in Older Versus Younger Breast Cancer Patients With Distinct Symptom Profiles.. <i>Frontiers in Genetics</i> , 2022 , 13, 869044	4.5	1
183	Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings.. <i>BMJ Open</i> , 2022 , 12, e057384	3	0
182	Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. <i>Neuro-Oncology Practice</i> , 2021 , 8, 137-147	2.2	1
181	Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. <i>Comprehensive Psychoneuroendocrinology</i> , 2021 , 8, 100099	1.1	
180	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3298-3306	12.9	3
179	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. <i>Neuro-Oncology Practice</i> , 2021 , 8, 460-474	2.2	0
178	Impact of age on the circadian visual system and the sleep-wake cycle in mus musculus. <i>Npj Aging and Mechanisms of Disease</i> , 2021 , 7, 10	5.5	1
177	Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vda0073	0.9	0
176	Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. <i>Cancers</i> , 2021 , 13,	6.6	1
175	SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. <i>Neuro-Oncology</i> , 2021 , 23, 1845-1858	1	1
174	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021 , 23, 468-477	1	10

173	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021 , 23, 1125-1138 ¹		3
172	Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. <i>Neuro-Oncology</i> , 2021 , 23, S30-S38	1	1
171	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab035	0.9	0
170	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021 , 8, 417-425	2.2	0
169	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021 , 23, 1337-1347	1	12
168	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021 , 23, 1360-1370	1	14
167	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021 , 142, 827-839	14.3	5
166	Report of Canonical - Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
165	Effects of Cognitive Reserve on Cognition in Individuals With Central Nervous System Disease. <i>Cognitive and Behavioral Neurology</i> , 2021 , 34, 245-258	1.6	1
164	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021 , 13,	6.6	1
163	Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. <i>Lancet Oncology</i> , 2020 , 21, 989-998	21.7	16
162	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020 , 16, 899-909	3.6	13
161	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1505-1515	1	8
160	High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 101	7.3	17
159	The prevalence of altered body image in patients with primary brain tumors: an understudied population. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 397-404	4.8	3
158	Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. <i>Neuro-Oncology</i> , 2020 , 22, 838-850	1	3
157	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology</i> , 2020 , 21, e97-e103	21.7	19
156	Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1579-1584	7.3	1

155	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 787-793	2.8	1
154	Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. <i>Neuro-Oncology Practice</i> , 2020 , 7, 38-51	2.2	5
153	Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review. <i>Neuro-Oncology Practice</i> , 2020 , 7, 477-489	2.2	1
152	Glioma patient-reported outcome assessment in clinical care - Authors' reply. <i>Lancet Oncology</i> , 2020 , 21, e231	21.7	
151	Letter to the Editor Re: Mohile et al. <i>Neuro-Oncology</i> , 2020 , 22, 1048-1049	1	1
150	Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 161-170	4.8	1
149	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa007	0.9	2
148	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 601452	5.3	1
147	Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 53-63	4.8	9
146	Impacts of Surgery on Symptom Burden and Quality of Life in Pituitary Tumor Patients in the Subacute Post-operative Period. <i>Frontiers in Oncology</i> , 2019 , 9, 299	5.3	4
145	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019 , 21, 837-853	1	37
144	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5799-5807	12.9	72
143	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019 , 21, 1100-1117	1	25
142	The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. <i>Neuro-Oncology Practice</i> , 2019 , 6, 473-478	2.2	3
141	Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 58	2.6	1
140	QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , 2019 , 21, vi203-vi204	1	78
139	QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi204-vi204	1	1
138	NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT. <i>Neuro-Oncology</i> , 2019 , 21, vi161-vi162	1	78

137	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019 , 21, vi137-vi137	1	10
136	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019 , 21, vi204-vi204	1	78
135	HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, vi111-vi112 ¹	1	78
134	HOUT-22. EVALUATING CLINICAL IMPACT UTILIZING THE RANO-PRO COLLABORATIVE'S STANDARDIZED PRIORITY CONSTRUCTS. <i>Neuro-Oncology</i> , 2019 , 21, vi116-vi117	1	78
133	QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS. <i>Neuro-Oncology</i> , 2019 , 21, vi205-vi206	1	1
132	RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS. <i>Neuro-Oncology</i> , 2019 , 21, vi207-vi207	1	2
131	Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 415-427	4.8	15
130	NIMG-32. CHALLENGES OF IMAGING INTERPRETATION TO PREDICT OLIGODENDROGLIOMA GRADE. <i>Neuro-Oncology</i> , 2019 , 21, vi168-vi168	1	78
129	Progress in rare central nervous system tumors. <i>Current Opinion in Neurology</i> , 2019 , 32, 895-906	7.1	3
128	Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. <i>Neuro-Oncology Practice</i> , 2019 , 6, 311-320	2.2	15
127	The lomustine crisis: awareness and impact of the 1500% price hike. <i>Neuro-Oncology</i> , 2019 , 21, 1-3	1	43
126	Clinical and demographic predictors of concussion resolution in adolescents: A retrospective study. <i>Applied Neuropsychology: Child</i> , 2019 , 8, 50-60	1.4	10
125	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019 , 84, 66-76	3.2	7
124	Quality improvement in neurology: Neuro-Oncology Quality Measurement Set. <i>Neuro-Oncology</i> , 2018 , 20, 531-537	1	3
123	Quality improvement in neurology: Neuro-oncology quality measurement set. <i>Neurology</i> , 2018 , 90, 652-658	6.8	5
122	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology, The</i> , 2018 , 19, e173-e180	21.7	23
121	Yoga Program for High-Grade Glioma Patients Undergoing Radiotherapy and Their Family Caregivers. <i>Integrative Cancer Therapies</i> , 2018 , 17, 332-336	3	29
120	Ependymomas arising outside of the central nervous system: A case series and literature review. <i>Journal of Clinical Neuroscience</i> , 2018 , 47, 202-207	2.2	11

119	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018 , 136, 227-237	14.3	52
118	Survivorship care planning in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2018 , 5, 3-9	2.2	6
117	QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS). <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi217	1	78
116	INNV-41. MY STORI -- A SYMPTOM TRACKING AND REPORTING INSTRUMENT MOBILE APPLICATION FOR CENTRAL NERVOUS SYSTEM CANCER PATIENTS. <i>Neuro-Oncology</i> , 2018 , 20, vi146-vi146	1	1
115	QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENTS EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi218	1	78
114	RARE-21. A DESCRIPTIVE REPORT OF PATIENTS WITH RARE CENTRAL NERVOUS SYSTEM (CNS) CANCERS ON AN NCI-CONNECT CANCER MOONSHOT IMMUNE CHECKPOINT INHIBITOR TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi240-vi240	1	78
113	INNV-43. NUCLEIC ACID ADEQUACY FROM ARCHIVED FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE FOR NEXT-GENERATION SEQUENCING (NGS) IN NATIONAL CANCER INSTITUTE (NCI)- NATURAL HISTORY STUDY (NHS) OF PRIMARY CNS TUMOR. <i>Neuro-Oncology</i> , 2018	1	78
112	HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi115-vi115	1	78
111	ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi13-vi13	1	1
110	INNV-38. THE NEURO-ONCOLOGY BRANCH TRANSLATIONAL RESEARCH IMMERSION PROGRAM: RESULTS FROM TWO YEARS OF DEVELOPMENT AND PARTICIPANT FEEDBACK. <i>Neuro-Oncology</i> , 2018 , 20, vi145-vi146	1	78
109	QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi215-vi215	1	78
108	EXTH-61. PARTNERSHIP FOR DEFINING THE IMPACT OF 12 SELECT RARE CNS TUMORS: A REPORT FROM CBTRUS AND THE NCI-CONNECT. <i>Neuro-Oncology</i> , 2018 , 20, vi98-vi98	1	78
107	HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT. <i>Neuro-Oncology</i> , 2018 , 20, vi113-vi113	1	78
106	IMMU-68. SINGLE-CELL PROTEOMIC ANALYSIS OF IMMUNE CELL RESPONSE TO CHECKPOINT BLOCKADE USING 30-PARAMETER FLOW CYTOMETRY. <i>Neuro-Oncology</i> , 2018 , 20, vi137-vi137	1	78
105	QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi216-vi216	1	78
104	RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM. <i>Neuro-Oncology</i> , 2018 , 20, vi241-vi241	1	78
103	INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCHS (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi145-vi145	1	78
102	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi164-vi164	1	2

101	PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP). <i>Neuro-Oncology</i> , 2018 , 20, vi72-vi72	1	1
100	QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS)..	1	78
99	RDNA-13. VALIDATION OF BEHAVIORAL ANALYSIS ACROSS AGE IN A MOUSE MODEL FOR FUTURE INVESTIGATION OF RADIATION-INDUCED HYPERSOMNOLENCE (RIH) IN PRIMARY BRAIN TUMOR (PBT) PATIENTS. <i>Neuro-Oncology</i> , 2018 , 20, vi224-vi224	1	78
98	Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. <i>Neuro-Oncology Practice</i> , 2018 , 5, 56-63	2.2	3
97	Survivorship in Neuro-Oncology. <i>Neuro-Oncology</i> , 2018 , 20, vii4-vii5	1	2
96	NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001. <i>Neuro-Oncology</i> , 2018 , 20, vi172-vi172	1	9
95	RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. <i>Neuro-Oncology</i> , 2018 , 20, vi241-vi241	1	2
94	Nursing Guide to Management of Major Symptoms in Patients with Malignant Glioma. <i>Seminars in Oncology Nursing</i> , 2018 , 34, 513-527	3.7	9
93	See brain cancer as more than just the sum of biology. <i>Nature</i> , 2018 , 561, S45	50.4	3
92	Association of genetic variants with fatigue in patients with malignant glioma. <i>Neuro-Oncology Practice</i> , 2018 , 5, 122-128	2.2	5
91	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018 , 20, 897-906	1	26
90	Describing Symptom Burden and Functional Status at the Diagnosis of Leptomeningeal Metastasis. <i>Oncology Nursing Forum</i> , 2018 , 45, 372-379	1.7	1
89	The impact and incidence of altered body image in patients with head and neck tumors: a systematic review. <i>Neuro-Oncology Practice</i> , 2018 , 5, 204-213	2.2	7
88	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017 , 35, 361-369	2.2	76
87	Sleep-wake disturbance in patients with brain tumors. <i>Neuro-Oncology</i> , 2017 , 19, 323-335	1	34
86	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017 , 19, 12-21	1	65
85	Clinical presentation and outcomes for adult ependymoma patients. <i>Cancer</i> , 2017 , 123, 494-501	6.4	14
84	The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. <i>Neuro-Oncology</i> , 2016 , 18, 252-60	1	67

83	Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. <i>Neuro-Oncology</i> , 2016 , 18 Suppl 2, ii1-ii12	1	18
82	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2016 , 18 Suppl 2, ii26-ii36	1	18
81	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2468-77	2.2	113
80	Hope and mood changes throughout the primary brain tumor illness trajectory. <i>Neuro-Oncology</i> , 2016 , 18, 119-25	1	15
79	Biology and management of ependymomas. <i>Neuro-Oncology</i> , 2016 , 18, 902-13	1	99
78	Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. <i>Neuro-Oncology</i> , 2016 , 18, 779-89	1	66
77	Interventions for the management of fatigue in adults with a primary brain tumour. <i>The Cochrane Library</i> , 2016 , 4, CD011376	5.2	21
76	Psycho-oncology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 305-133		
75	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015 , 129, 585-96	14.3	211
74	Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 341-8	4.8	8
73	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3340-6	12.9	23
72	Significant predictors of patients' uncertainty in primary brain tumors. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 507-15	4.8	4
71	Venous thromboembolism (VTE) and glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 87-94	4.8	43
70	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 401-10	4.8	43
69	Wound healing complications in brain tumor patients on Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 501-6	4.8	14
68	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015 , 17, 440-7	1	83
67	C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. <i>Brain Tumor Pathology</i> , 2015 , 32, 105-11	3.2	16
66	Exploring the Cancer Experiences of Young Adults in the Context of Stem Cell Transplantation. <i>Cancer Nursing</i> , 2015 , 38, 260-9	2.6	2

65	Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials. <i>Neuro-Oncology Practice</i> , 2015 , 2, 2-5	2.2	15
64	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015 , 27, 728-43	24.3	672
63	The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. <i>Neuro-Oncology</i> , 2015 , 17, 1114-20	1	16
62	A randomized trial of bevacizumab for newly diagnosed glioblastoma. <i>New England Journal of Medicine</i> , 2014 , 370, 699-708	59.2	1775
61	Personal health records as portal to the electronic medical record. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 1-6	4.8	32
60	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1634-5	2.2	2
59	Response to Lai et al., "development of a symptom index for patients with primary brain tumors". <i>Value in Health</i> , 2014 , 17, 752-3	3.3	
58	Envisioning the future in symptom science. <i>Nursing Outlook</i> , 2014 , 62, 346-51	2.7	24
57	Pregnancy and glial brain tumors. <i>Neuro-Oncology</i> , 2014 , 16, 1289-94	1	56
56	Interventions for the management of fatigue in adults with a primary brain tumour 2014 ,		2
55	Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 519-28	5.4	18
54	Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review. <i>Oncology Nursing Forum</i> , 2014 , 41, E355-65	1.7	17
53	Primary brain tumors and posterior reversible encephalopathy syndrome. <i>Neuro-Oncology Practice</i> , 2014 , 1, 184-190	2.2	9
52	Impact of recall period on primary brain tumor patient's self-report of symptoms. <i>Neuro-Oncology Practice</i> , 2014 , 1, 55-63	2.2	9
51	Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. <i>Neurosurgery</i> , 2014 , 75, 205-14; discussion 213-4	3.2	30
50	Personal health records, symptoms, uncertainty, and mood in brain tumor patients. <i>Neuro-Oncology Practice</i> , 2014 , 1, 64-70	2.2	6
49	Venous thromboembolism (VTE) and glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2033-2033	2.2	1
48	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4085-91	2.2	623

47	Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials. <i>Current Oncology Reports</i> , 2013 , 15, 27-32	6.3	9
46	Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. <i>Journal of Neuro-Oncology</i> , 2013 , 115, 513-20	4.8	13
45	Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4076-84	2.2	98
44	Uncertainty, mood states, and symptom distress in patients with primary brain tumors: analysis of a conceptual model using structural equation modeling. <i>Cancer</i> , 2013 , 119, 2796-806	6.4	21
43	Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. <i>Brain Pathology</i> , 2013 , 23, 584-94	6	45
42	Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2004-2004	2.2	12
41	Brain tumor symptoms as antecedents to uncertainty: an integrative review. <i>Journal of Nursing Scholarship</i> , 2012 , 44, 145-55	3.6	8
40	Predictors of survival among older adults with ependymoma. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 183-98	4.8	25
39	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , 2012 , 13, e196-204	21.7	43
38	Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). <i>Journal of Neuro-Oncology</i> , 2012 , 110, 293-300	4.8	17
37	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012 , 118, 5026-37	6.4	19
36	Glioblastoma. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 485-506	3	13
35	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012 , 123, 727-38	14.3	131
34	Management of treatment-associated toxicities of anti-angiogenic therapy in patients with brain tumors. <i>Neuro-Oncology</i> , 2012 , 14, 1203-14	1	45
33	Practical strategies for management of fatigue and sleep disorders in people with brain tumors. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv65-72	1	53
32	Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. <i>Neuroepidemiology</i> , 2012 , 39, 116-24	5.4	54
31	Cuidar de un adulto con un tumor cerebral primario maligno. <i>Nursing (Ed Española)</i> , 2011 , 29, 8-13	0	
30	Caring for an adult with a malignant primary brain tumor. <i>Nursing</i> , 2011 , 41, 28-33; quiz 33-4	0.5	3

29	A case of soft tissue metastasis from glioblastoma and review of the literature. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 167-72	4.8	16
28	Patient profiling for treatment toxicity: potential use of clinical and genomic factors. <i>Current Oncology Reports</i> , 2011 , 13, 37-41	6.3	1
27	The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. <i>Cancer</i> , 2011 , 117, 3222-8	6.4	28
26	Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. <i>Cancer</i> , 2011 , 117, 5133-41	6.4	28
25	Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2467-74	2.2	87
24	Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. <i>Neuro-Oncology</i> , 2010 , 12, 862-70	1	79
23	Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. <i>Journal of Neurosurgery: Spine</i> , 2010 , 12, 421-30	2.8	29
22	Seizure risk in brain tumor patients with conversion to generic levetiracetam. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 137-41	4.8	7
21	Risk factors for fatigue severity in primary brain tumor patients. <i>Cancer</i> , 2010 , 116, 2707-15	6.4	53
20	Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. <i>Neuro-Oncology</i> , 2009 , 11, 825-32	1	55
19	Head's up on the treatment of malignant glioma patients. <i>Oncology Nursing Forum</i> , 2009 , 36, E232-40	1.7	9
18	Clinical utility of the MDASI-BT in patients with brain metastases. <i>Journal of Pain and Symptom Management</i> , 2009 , 37, 331-40	4.8	33
17	Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2181-7	3.1	50
16	Increased intracranial pressure. <i>Clinical Journal of Oncology Nursing</i> , 2008 , 12, 37-41	1.1	8
15	Antiepileptic drugs for preventing seizures in people with brain tumors. <i>The Cochrane Library</i> , 2008 , CD004424	6.7	67
14	Use of complementary and alternative medical therapy by patients with primary brain tumors. <i>Current Neurology and Neuroscience Reports</i> , 2008 , 8, 264-8	6.6	18
13	Net clinical benefit: functional endpoints in brain tumor clinical trials. <i>Current Oncology Reports</i> , 2007 , 9, 60-5	6.3	14
12	Seizures in people with cancer. <i>Clinical Journal of Oncology Nursing</i> , 2007 , 11, 33-7	1.1	4

11	Complementary and alternative medicine use and quality of life in patients with primary brain tumors. <i>Journal of Pain and Symptom Management</i> , 2006 , 32, 148-54	4.8	34
10	Chemotherapy-induced peripheral neuropathy. <i>Oncology Nursing Forum</i> , 2005 , 32, 305-11	1.7	90
9	Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. <i>Oncology Nursing Forum</i> , 2005 , 32, 669-76	1.7	48
8	Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. <i>Journal of Nursing Scholarship</i> , 2004 , 36, 197-206	3.6	82
7	Central nervous system toxicity from cancer treatment. <i>Current Oncology Reports</i> , 2004 , 6, 11-9	6.3	9
6	The treatment of neoplastic meningitis. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1929-35	4	4
5	Imaging techniques in neuro-oncology. <i>Seminars in Oncology Nursing</i> , 2004 , 20, 231-239	3.7	18
4	Symptoms experience: a concept analysis. <i>Oncology Nursing Forum</i> , 2003 , 30, 601-6	1.7	165
3	Seize the moment to learn about epilepsy in people with cancer. <i>Clinical Journal of Oncology Nursing</i> , 2003 , 7, 163-9	1.1	10
2	Glial tumors--new approaches in chemotherapy. <i>Journal of Neuroscience Nursing</i> , 2002 , 34, 326-30	1.5	1
1	Chemotherapy of astrocytomas: an overview. <i>Seminars in Oncology Nursing</i> , 1998 , 14, 18-25	3.7	3